AgomAb Therapeutics
Franklin Rooseveltlaan 348 126
9000 Gent
BE
AgomAb Therapeutics
Foundation date
13/04/2017
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
- #Diseases of the blood and blood-forming organs - immune disorders
- #Endocrine - nutritional and metabolic diseases
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Our unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
0604 '23
Innovation for Health 2023
Event by: Hyphen Projects
Latest news
More news-
Imec-onderzoekers leggen basis voor in vivo detectie van traag groeiende hersentumoren, met dank aan hyperspectrale camera
Friday February 3rd 2023
Read more
-
Weber joins Vivactis Group to reinforce its Market Access capabilities
Thursday February 2nd 2023
Read more
-
Mithra CDMO announces collaboration with VaRi Bioscience for the development of a long-acting product in women’s health
Thursday February 2nd 2023
Read more